Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

For instance, Dr. Javitt never voluntarily disclosed to Relief the fact that an Emergency Use Authorization for aviptadil had been denied by the FDA in November 2020 – an intentional omission that caused Relief to not be able to report this obviously material information for over a month. This behavior not only compromises Relief’s ability to advance development of the drug in territories worldwide but also puts Relief at regulatory risk due to an inability to fulfill its disclosure requirements as a publicly traded company (page 6)

https://www.dropbox.com/s/zmnr3ynegprpz97/not_assigned_relief_therapeutics_ho_v_relief_therapeutics_ho_complaint_2%20%281%29.pdf?dl=0